This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amicus Fabry Drug Fails Pivotal Trial

Stocks in this article: FOLD GSK SNY

CRANBURY, NJ ( TheStreet) -- An experimental therapy from Amicus Therapeutics (FOLD - Get Report) and GlaxoSmithKline (GSK - Get Report) failed to improve kidney response in Fabry disease patients compared to placebo in a late-stage study, the companies disclosed Wednesday night.

The negative study result is a significant setback for the drug, known as Amigal, and will raise more questions about the viability of Amicus' "pharmacological chaperone" technology. A similar Amicus drug for Gaucher disease failed in 2009.

Amicus shares closed Wednesday at $5.77 but fell 55% to $2.60 in after-hours trading.

Fabry is a rare, inherited disease in which a genetic mutation stops an enzyme from breaking down a fatty substance known as globotriaosylceramide, or GL3. The buildup of GL3 in blood vessels throughout the body causes severe damage to kidneys, heart, brain, and other organ systems.

The phase III study enrolled Fabry patients with severe disease, meaning they have high levels of GL3 built up in their kidneys. The patients were randomized in a blinded fashion to treatment with Amigal or a placebo for six months. The study's primary endpoint compared response to Amigal versus placebo at six months, with response defined as a 50% reduction in GL3 levels measured via a kidney biopsy.

After six months, 13 of 32, or 41%, of Amigal-treated patients demonstrated a kidney response compared to 9 of 32, or 28%, of the placebo-treated patients. The difference, while favoring Amigal, was not statistically significant, which is why the study failed.

Amicus and Glaxo provided little explanation in their joint announcement Wednesday night to explain the negative results. The 28% placebo response was unusually high while the 41% of Amigal patients who responded was lower than the results observed in previous studies.

Moreover, the median reduction of GL3 in the kidneys of placebo patients was just 6% from baseline through six months, which seems very low given 28% of placebo patients demonstrated a kidney response per the study's definition.

By comparison, the median reduction of GL3 in the kidneys of Amigal patients was 41%.

Amicus and Glaxo chose not to hold a conference call Wednesday night to discuss the study results.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs